Chief Medical Officer Zach Roberts said the company expects to report initial data in April from its ALPHA3 study, a ...

Citi's 2026 Virtual Oncology Leadership Summit February 18, 2026 12:15 PM ESTCompany ParticipantsZachary Roberts ...

Minimal residual disease, or MRD, testing may have the potential to offer peace of mind to survivors of breast cancer, as a ...

Quest Diagnostics debuts a new blood test for myeloma MRD, offering NGS-level sensitivity and a less invasive alternative to bone marrow biopsies. Quest Diagnostics has announced the launch of a novel ...

Q4 2025 earnings call recap: clonoSEQ MRD growth, 2026 revenue guidance, margins, cash burn and risks—read now.

Quest Diagnostics delivered a Q4 performance that exceeded Wall Street’s revenue and earnings expectations, prompting a positive market reaction. Management attributed this outcome to strong organic ...

Quest Diagnostics has rolled out an ultrasensitive blood test to monitor multiple myeloma treatment, potentially sparing patients from more invasive and costly bone marrow aspirations. Quest Flow ...

SECAUCUS, N.J., Feb. 2, 2026 /PRNewswire/ --Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the launch of a novel blood test that uses advanced ...

Medicare will reimburse the company’s NeXT Personal molecular residual disease (MRD) test when used to monitor patients with ...

Quest Diagnostics (DGX) just paired a strong fourth quarter and full year 2025 with a confident 2026 outlook, a higher dividend, expanded buybacks, and new high value tests such as its myeloma MRD ...